325 related articles for article (PubMed ID: 31748226)
1. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
Lin GL; Wilson KM; Ceribelli M; Stanton BZ; Woo PJ; Kreimer S; Qin EY; Zhang X; Lennon J; Nagaraja S; Morris PJ; Quezada M; Gillespie SM; Duveau DY; Michalowski AM; Shinn P; Guha R; Ferrer M; Klumpp-Thomas C; Michael S; McKnight C; Minhas P; Itkin Z; Raabe EH; Chen L; Ghanem R; Geraghty AC; Ni L; Andreasson KI; Vitanza NA; Warren KE; Thomas CJ; Monje M
Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748226
[TBL] [Abstract][Full Text] [Related]
2. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
[TBL] [Abstract][Full Text] [Related]
3. Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas.
Jane EP; Reslink MC; Gatesman TA; Halbert ME; Miller TA; Golbourn BJ; Casillo SM; Mullett SJ; Wendell SG; Obodo U; Mohanakrishnan D; Dange R; Michealraj A; Brenner C; Agnihotri S; Premkumar DR; Pollack IF
Mol Oncol; 2023 Sep; 17(9):1821-1843. PubMed ID: 37014128
[TBL] [Abstract][Full Text] [Related]
4. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Grasso CS; Tang Y; Truffaux N; Berlow NE; Liu L; Debily MA; Quist MJ; Davis LE; Huang EC; Woo PJ; Ponnuswami A; Chen S; Johung TB; Sun W; Kogiso M; Du Y; Qi L; Huang Y; Hütt-Cabezas M; Warren KE; Le Dret L; Meltzer PS; Mao H; Quezado M; van Vuurden DG; Abraham J; Fouladi M; Svalina MN; Wang N; Hawkins C; Nazarian J; Alonso MM; Raabe EH; Hulleman E; Spellman PT; Li XN; Keller C; Pal R; Grill J; Monje M
Nat Med; 2015 Jun; 21(6):555-9. PubMed ID: 25939062
[TBL] [Abstract][Full Text] [Related]
5. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
6. Targeting NAD
Jane EP; Premkumar DR; Thambireddy S; Golbourn B; Agnihotri S; Bertrand KC; Mack SC; Myers MI; Chattopadhyay A; Taylor DL; Schurdak ME; Stern AM; Pollack IF
Mol Cancer Res; 2020 Jul; 18(7):1004-1017. PubMed ID: 32238439
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
[TBL] [Abstract][Full Text] [Related]
8. PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
Brown EJ; Balaguer-Lluna L; Cribbs AP; Philpott M; Campo L; Browne M; Wong JF; Oppermann U; Carcaboso ÁM; Bullock AN; Farnie G
Sci Rep; 2024 Jan; 14(1):328. PubMed ID: 38172189
[TBL] [Abstract][Full Text] [Related]
9. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
10. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q; Niu W; Pan H
Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
[TBL] [Abstract][Full Text] [Related]
12. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
[TBL] [Abstract][Full Text] [Related]
13. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
[TBL] [Abstract][Full Text] [Related]
14. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
[TBL] [Abstract][Full Text] [Related]
15. Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma.
Sharma M; Barravecchia I; Magnuson B; Ferris SF; Apfelbaum A; Mbah NE; Cruz J; Krishnamoorthy V; Teis R; Kauss M; Koschmann C; Lyssiotis CA; Ljungman M; Galban S
Neoplasia; 2023 Oct; 44():100931. PubMed ID: 37647805
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.
Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
[TBL] [Abstract][Full Text] [Related]
17. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
18. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
[No Abstract] [Full Text] [Related]
19. Advances in Treatment of Diffuse Midline Gliomas.
Cacciotti C; Wright KD
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):849-856. PubMed ID: 37921944
[TBL] [Abstract][Full Text] [Related]
20. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
